Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Cullinan Therapeutics Inc.
Headquarters: Cambridge, MA, United States of America
Website: http://www.cullinanoncology.c...
Year Founded: 2016
Status: Public
Industry Sector: HealthTechnology
CEO: Nadim Ahmed
Number Of Employees: 111
Enterprise Value: $258,104,780
PE Ratio: -2.31
Exchange/Ticker 1: NASDAQ:CGEM
Exchange/Ticker 2: N/A
Latest Market Cap: $433,579,808
BioCentury | Mar 29, 2025
Product Development
Bispecifics for I&I: Bypassing combination complexity
At least 30 companies have bispecific antibodies in development for autoimmune and inflammatory diseases
BioCentury | Feb 5, 2025
Product Development
Biotechs make inroads to precision medicine, solving long-standing problems
70% of new precision medicines approved by FDA in past three years were not sponsored by major pharmas
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New I&I indications take center stage
Inflammation and immunology readouts to define new priority indications, modality opportunities in immune reset
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: Bispecifics poised to enter new era
Decade after first approval, bispecifics on the precipice of going mainstream
BioCentury | Nov 21, 2024
Management Tracks
Boshoff to succeed Dolsten as Pfizer CSO
Plus: Hwang joins Metaphore, Flagship and updates from FDA, MHRA, ArrePath, ABT, Unnatural, Thryv and more
BioCentury | Nov 6, 2024
Management Tracks
SOBI to propose David Meek as chair
Plus: Seaport hires Lauren White as CFO, and updates from Tarsus and Takeda
BioCentury | Oct 22, 2024
Product Development
Newco trend watch: Clusters of launches point to areas undergoing derisking
Oligo delivery to the kidney, and two emerging use cases for T cell engagers, each get newcos; most with mega-
BioCentury | Sep 10, 2024
Emerging Company Profile
Candid: Bispecifics for autoimmunity, leveraging Chinese oncology innovation
Ken Song’s post-RayzeBio venture pulled together two licensing deals, an M&A transaction and three financings totaling $370M
BioCentury | Apr 30, 2024
Product Development
Clinical report: Academic trials signal autoimmune opportunities for T cell engagers
Plus: Results from Lilly’s Verzenio, antibody-drug conjugate Enhertu, and programs from Newron and Annovis
BioCentury | Apr 19, 2024
Finance
Public equity report: Depression data drive Intra-Cellular’s $500M raise
Plus public offerings for Biohaven and TScan, and PIPEs for Cullinan and Zura
Items per page:
1 - 10 of 11